The Latest Breaking News from EW

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 16.51% on an annualized basis producing an average annual return of 22.72%. Currently, Edwards Lifesciences has a market capitalization of $55.48 billion.

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…

The actor announced his departure last week.

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 14.71% on an annualized basis producing an average annual return of 21.87%. Currently, Edwards Lifesciences has a market capitalization of $69.03 billion.

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

Growing demand from an aging population to track their diseases and increased focus on critical surgical procedures with lesser COVID-19 pressures on hospitals make the medical devices industry’s prospects bright. Moreover, the integration of emerging technologies and continued innovations should drive the industry’s growth. Therefore, prominent players in this space,…

Edwards Lifesciences topped Wall Street's first-quarter views on Tuesday, but EW stock fell in after-hours action.

The market rally remains under pressure and divided. Investors should keep exposure modest and focus on leading sectors.

The Dow Jones rose as the stock market powered back. Airline stocks popped on a mask mandate move. WeWork stock rocketed on a bullish call.

Edwards Lifesciences is the IBD Stock Of The Day as the easing Covid pandemic allows for bullish growth in TAVR procedures in the U.S.

Pfizer and Raytheon are among 5 stocks near buy points that offer protection from geopolitics and aggressive rate-hikes.